EXACT Sciences Corporation · Marlborough, MA United States ·(NASDAQ (GM): EXAS)
Company Description
View EXACT Sciences Corporation Locations On A US Map
This link will open in a new window
This link will open in a new window Guesstimates aren't good enough when diagnosing a deadly cancer, so EXACT Sciences aims for accuracy. The firm develops non-invasive tests for the early detection of colorectal cancer and precancerous lesions. Its products isolate DNA in stool samples, using its Effipure technology, then identify genetic mutations associated with cancer. Colorectal cancer is a common (and one of the deadliest) cancers, and EXACT believes its method is superior to existing diagnostic methods because it may be able to discern colorectal cancer in its early stages, when it is most treatable. However, facing several product development setbacks, the company is undergoing a strategic reorganization. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key EXACT Sciences Corporation Financials
| Company Type | Public - NASDAQ (GM): EXAS Single Location |
| Fiscal Year-End | December |
| 2008 Sales (mil.) | -$0.9 |
| 2008 Employees | 4 |
EXACT Sciences Corporation Executives
11 executives listed for EXACT Sciences Corporation's Marlborough, MA location.
| Title | Name & Bio | Contact |
| Chairman | Patrick Zenner | Network |
| President, CEO, and Director | Kevin Conroy | Network |
| SVP and CFO | Maneesh Arora | Network |
Competition
Competitive Landscape for EXACT Sciences Corporation
Demand for biotechnology research in the fields of medicine, agriculture, food, and science is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research. The industry is capital intensive: average annual revenue per worker is more than $350,000. Biotech firms face stiff competition from pharmaceutical and other companies seeking to be first with a new product or discovery. To read the full description, subscribe now.Top EXACT Sciences Corporation Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!